Telomir Pharmaceuticals (NASDAQ:TELO) Trading Up 3.8% – Still a Buy?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) shares were up 3.8% on Monday . The stock traded as high as $4.42 and last traded at $4.38. Approximately 41,805 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 78,525 shares. The stock had previously closed at $4.22.

Telomir Pharmaceuticals Price Performance

The firm has a 50-day moving average of $5.31 and a two-hundred day moving average of $5.18.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.05) EPS for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TELO. Bank of New York Mellon Corp purchased a new position in Telomir Pharmaceuticals in the second quarter valued at about $241,000. Suncoast Equity Management raised its position in Telomir Pharmaceuticals by 109.9% in the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock valued at $329,000 after purchasing an additional 26,803 shares during the period. Finally, Beaird Harris Wealth Management LLC raised its position in Telomir Pharmaceuticals by 212.9% in the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after purchasing an additional 9,950 shares during the period.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.